MedTrace Logo

A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome

NCT07319832 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2026-03-13

No results posted yet for this study

Summary

Short Bowel Syndrome (SBS) is a rare condition that happens when a large part of the bowel (also called intestine) is missing or has been removed because of illness or surgery. In children, SBS means that the intestine cannot absorb enough food, water and important part of food the body needs (called nutrients) because a big part of it has been removed, bypassed or did not develop normally at birth and the children need support through a vein (parenteral support or PS) for more than 42 days to stay healthy and keep their energy. SBS in children is defined mainly by how well the intestine works and how long the children need this support, not just by how long the intestine is.

The main aim of the study is to learn how well the teduglutide works in children and teenagers with SBS and who need PS. Another aim is to find out how well teduglutide works for participants to lower the amount of PS needed. Also, the study wants to learn more about how safe teduglutide is in children and teenagers with SBS who need PS.

The study will review data already existing in the medical records of participants as well as collect new data during the study.

Conditions

  • Short Bowel Syndrome (SBS)

Interventions

OTHER

No Intervention

No Intervention

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-05
Primary Completion
2027-04-30
Completion
2027-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07319832 on ClinicalTrials.gov